Melanie M. Hagleitner
Research Subjects
Melanie M. Hagleitner has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Dunja M.W.M Te Loo
8 shared publications- Eveline S. J. M. de Bont
Department of Pediatric Oncology/Hematology, University of Groningen, Groningen, The Netherlands
8 shared publications - Frank N. van Leeuwen
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
8 shared publications H.W. Bart Schreuder
8 shared publicationsHanneke I. Vos
8 shared publications- Hans Gelderblom
Leiden University Medical Center Leiden Netherlands
8 shared publications
Latest Publications
- Open Access
NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.
Open AccessNOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
Twenty percent of children with T-cell lymphoblastic lymphoma (T-LBL) will relapse and have an extremely poor outcome. Currently, we can identify a genetically low-risk subgroup in pediatric T-LBL, yet these high-risk patients who need intensified or alternative treatment options remain undetected. Therefore, there is an urgent need to recognize these high-risk T-LBL patients through identification of molecular characteristics and biomarkers. By using RNA sequencing which was performed in 29/49 T-LBL patients who were diagnosed in the Princess Maxima Center for Pediatric Oncology between 2018-2023, we discovered a previously unknown high-risk biological subgroup of children with T-LBL. This subgroup is characterized by NOTCH1 gene fusions, found in 21% of our T-LBL cohort (6/29). All patients presented with a large mediastinal mass, pleural/pericardial effusions, and absence of blasts in the bone marrow, blood, and central nervous system. Blood CCL17 (C-C Motif Chemokine Ligand 17, TARC) levels were measured at diagnosis in 26/29 patients, and all six patients with NOTCH1 gene fusions patients exclusively expressed highly elevated blood CCL17 levels, defining a novel and previously not known clinically relevant biomarker for T-cell lymphoblastic lymphoma. Four out of these six patients relapsed during therapy, a fifth developed a therapy related acute myeloid leukemia during maintenance therapy. These data indicate that T-LBL patients with a NOTCH1 fusion have a high risk of relapse which can be easily identified using a blood CCL17 screening at diagnosis. Further molecular characterization through NOTCH1 gene fusion analysis offers these patients the opportunity for treatment intensification or new treatment strategies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 3. Genetic variants associated with 5-year PFS
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 3. Genetic variants associated with 5-year PFS
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 2. Genetic variants associated with histologic response
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 2. Genetic variants associated with histologic response
- Open Access
- 1 July 2021
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (7) , e513-e523
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
- 1 July 2021
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (7) , e513-e523
Open AccessSevere toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia